Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers

Sarang S. Talwelkar; Ashwini S. Nagaraj; Jennifer R. Devlin; Annabrita Hemmes; Swapnil Potdar; Elina A. Kiss; Pipsa Saharinen; Kaisa Salmenkivi; Mikko I. Mäyränpää; Krister Wennerberg; Emmy W. Verschuren

doi:10.1158/1535-7163.MCT-18-0573

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers

Sarang S. Talwelkar, Ashwini S. Nagaraj, Jennifer R. Devlin, Annabrita Hemmes, Swapnil Potdar, Elina A. Kiss, Pipsa Saharinen, Kaisa Salmenkivi, Mikko I. Mäyränpää, Krister Wennerberg, Emmy W. Verschuren

Wennerberg Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

6 Citationer (Scopus)

18 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	Molecular Cancer Therapeutics
Vol/bind	18
Udgave nummer	10
Sider (fra-til)	1863-1874
ISSN	1535-7163
DOI	https://doi.org/10.1158/1535-7163.MCT-18-0573
Status	Udgivet - 2019

Adgang til dokumentet

10.1158/1535-7163.MCT-18-0573

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung CancersAccepteret manuskript, 2,36 MB

Citationsformater

Talwelkar, S. S., Nagaraj, A. S., Devlin, J. R., Hemmes, A., Potdar, S., Kiss, E. A., Saharinen, P., Salmenkivi, K., Mäyränpää, M. I., Wennerberg, K., & Verschuren, E. W. (2019). Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers. Molecular Cancer Therapeutics, 18(10), 1863-1874. https://doi.org/10.1158/1535-7163.MCT-18-0573

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers. / Talwelkar, Sarang S.; Nagaraj, Ashwini S.; Devlin, Jennifer R.; Hemmes, Annabrita; Potdar, Swapnil; Kiss, Elina A.; Saharinen, Pipsa; Salmenkivi, Kaisa; Mäyränpää, Mikko I.; Wennerberg, Krister; Verschuren, Emmy W.

I: Molecular Cancer Therapeutics, Bind 18, Nr. 10, 2019, s. 1863-1874.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Talwelkar, SS, Nagaraj, AS, Devlin, JR, Hemmes, A, Potdar, S, Kiss, EA, Saharinen, P, Salmenkivi, K, Mäyränpää, MI, Wennerberg, K & Verschuren, EW 2019, 'Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers', Molecular Cancer Therapeutics, bind 18, nr. 10, s. 1863-1874. https://doi.org/10.1158/1535-7163.MCT-18-0573

Talwelkar, Sarang S. ; Nagaraj, Ashwini S. ; Devlin, Jennifer R. ; Hemmes, Annabrita ; Potdar, Swapnil ; Kiss, Elina A. ; Saharinen, Pipsa ; Salmenkivi, Kaisa ; Mäyränpää, Mikko I. ; Wennerberg, Krister ; Verschuren, Emmy W. / Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers. I: Molecular Cancer Therapeutics. 2019 ; Bind 18, Nr. 10. s. 1863-1874.

@article{bb89b05017ed45b28811d99b1bbdeded,

title = "Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers",

author = "Talwelkar, {Sarang S.} and Nagaraj, {Ashwini S.} and Devlin, {Jennifer R.} and Annabrita Hemmes and Swapnil Potdar and Kiss, {Elina A.} and Pipsa Saharinen and Kaisa Salmenkivi and M{\"a}yr{\"a}np{\"a}{\"a}, {Mikko I.} and Krister Wennerberg and Verschuren, {Emmy W.}",

year = "2019",

doi = "10.1158/1535-7163.MCT-18-0573",

language = "English",

volume = "18",

pages = "1863--1874",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research (A A C R)",

number = "10",

}

TY - JOUR

T1 - Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers

AU - Talwelkar, Sarang S.

AU - Nagaraj, Ashwini S.

AU - Devlin, Jennifer R.

AU - Hemmes, Annabrita

AU - Potdar, Swapnil

AU - Kiss, Elina A.

AU - Saharinen, Pipsa

AU - Salmenkivi, Kaisa

AU - Mäyränpää, Mikko I.

AU - Wennerberg, Krister

AU - Verschuren, Emmy W.

PY - 2019

Y1 - 2019

U2 - 10.1158/1535-7163.MCT-18-0573

DO - 10.1158/1535-7163.MCT-18-0573

M3 - Journal article

C2 - 31320402

VL - 18

SP - 1863

EP - 1874

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -